Stockreport

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences, Inc.  (ENVB) 
PDF Enveric expects to file Investigational New Drug application for EB-003 in early 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” [Read more]